Yanran He
Impact in
- Oncology top 10%
- CAR-T cell therapy research
-
- Traditional Chinese Medicine Analysis
Papers in
- Oncology 9
- CAR-T cell therapy research 8
-
- Systemic Lupus Erythematosus Research 3
- Co-authors
- Jie Yu (3 shared papers)Ronghua Zhao (3 shared papers)Wen Gu (2 shared papers)Pei Lin (2 shared papers)Ruifen Sun (1 shared paper)Hans Wilhelm Schreiber (5 shared papers)David M. Kranz (3 shared papers)Xingxin Yang (1 shared paper)
- Journals
- JCI Insight (2 papers)Journal of Ethnopharmacology (2 papers)Cell (2 papers)Nature Medicine (1 paper)Med (1 paper)
- Partner nations
- ChinaUnited StatesDenmark
In The Last Decade
Yanran He
16 papers receiving 609 citations
Yanran He's Hit Papers
Peers
Comparison fields: 5 of 52
- Oncology 270
- Complementary and alternative medicine 40
- Immunology 81
- Urology 25
- Rheumatology 40
Countries citing papers authored by Yanran He
This map shows the geographic impact of Yanran He's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanran He with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanran He more than expected).
Fields of papers citing papers by Yanran He
This network shows the impact of papers produced by Yanran He. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanran He. The network helps show where Yanran He may publish in the future.
Co-authors
The 25 scholars most cited alongside Yanran He, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis Hit paper breakdown → | 2024 | 213 |
| 2 | 2014 | 81 | |
| 3 | 2019 | 52 | |
| 4 | An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis Hit paper breakdown → | 2025 | 48 |
| 5 | 2015 | 40 | |
| 6 | 2020 | 38 | |
| 7 | 2019 | 29 | |
| 8 | 2019 | 27 | |
| 9 | 2025 | 25 | |
| 10 | 2019 | 20 | |
| 11 | 2025 | 20 | |
| 12 | 2023 | 13 | |
| 13 | 2013 | 11 | |
| 14 | 2021 | 9 | |
| 15 | 2025 | 2 | |
| 16 | 2018 | 1 | |
| 17 | 2025 | 0 |
About Yanran He
Yanran He is a scholar working on Oncology, Rheumatology, Immunology, Urology and Dermatology, having authored 17 papers that have together received 629 indexed citations. Recurring topics across this work include CAR-T cell therapy research (8 papers), Systemic Lupus Erythematosus Research (3 papers), Dermatology and Skin Diseases (1 paper), Immune cells in cancer (1 paper), Atherosclerosis and Cardiovascular Diseases (1 paper), Monoclonal and Polyclonal Antibodies Research (1 paper), T-cell and B-cell Immunology (1 paper) and Psoriasis: Treatment and Pathogenesis (1 paper). The work is most often cited by research in Oncology (270 citations), Complementary and alternative medicine (40 citations), Immunology (81 citations), Urology (25 citations) and Rheumatology (40 citations). Yanran He has collaborated with scholars based in China, United States and Denmark. Frequent co-authors include Jie Yu, Ronghua Zhao, Wen Gu, Pei Lin, Ruifen Sun, Hans Wilhelm Schreiber, David M. Kranz, Xingxin Yang, Henrik Clausen and Fengjiao Li. Their work appears in journals such as JCI Insight, Journal of Ethnopharmacology, Cell, Nature Medicine and Med.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.